Healthcare stocks across Asia were not spared from the recent market turmoil. This sell-off coupled with unabated top-line growth has brought valuations to historic lows and created very attractive entry points for investors.

*By Oliver Kubli, Portfolio Manager Bellevue Asia Pacific Healthcare Fonds, Bellevue Asset Management*

The healthcare market in emerging Asian economies is a giant growth market. The region accounts for 60 percent of the world's population. There are more than 3 billion people in China, India and Indonesia alone. Meanwhile, the middle class continues to grow relative to the total population. This means growing purchasing power and clearly stronger demand for goods and services from consumer and leisure-related industries and, of course, from the healthcare industry too.
An additional development underway in the healthcare sector is worthy of special mention: Asia populations are also steadily graying. Within approximately one generation, by about 2050, about one billion people in the region will be older than 60, and about half of them will be in China alone.

**Major Reforms**

Against this backdrop, access to high-quality healthcare products and services that ordinary citizens can afford is critical. Government policy will, of course, shape the future development and modernization of national healthcare systems. Emerging Asian countries have been particularly active in pursuing sweeping healthcare reforms, in order to keep up with exploding demand.

Sector growth forecasts are correspondingly attractive. We expect the healthcare industry in Asian emerging markets to grow twice as fast as the respective gross national products over the next few years.

**Excessive Correction in China**

Turning to China, Beijing announced one of its first major healthcare reforms in 2015 when it introduced mandatory bioequivalence testing of generics, among other measures. Three years later, the first government tenders and centralized procurement processes for generics were introduced. Such action was initially greeted with uncertainty by investors. For patients, however, it has improved the quality, access and affordability of healthcare goods and services.

The recent correction, and not only in healthcare but across the Chinese stock market, can be traced to a mix of foreign policy tension (US-China confrontations), the Ukraine war, and Chinese public policy decisions. The latter include a stringent zero-COVID policy that has raised some eyebrows and a sweeping regulatory crackdown on technology companies among others.

**Government Action Squarely Focused**

What is often overlooked with these issues is that, unlike most countries in the West, inflation is not a concern in China and therefore its government is in a better position to support the economy through accommodative monetary and fiscal policies. What is particularly important when it comes to healthcare is that government action is squarely focused on modernizing the entire system, at every level of the value chain. Supporting research and development activities
is absolutely vital in order to satisfy the tremendous demand with domestically developed products and services over the medium to long term.

A standout example of the progress being made by China's homegrown healthcare industry is Legend Biotech. Together with its partner Johnson & Johnson, it presented efficacy data from a personalized cell therapy trial in patients with multiple myeloma, the second most common type of blood cancer, that is in a class of its own. The cell therapy was approved by the US FDA at the end of February 2022.

Despite the occasionally brutal stock market sell-offs, Chinese healthcare stocks have outperformed the US stock market by more than 1,000 percent over the past 18 years.

Allocation to Chinese Names Increased

About 40 percent of the Bellevue Asia Pacific Healthcare Fund (ISIN B-USD LU1587984847) is currently invested in China. Its China allocation has steadily increased during recent weeks in view of very attractive valuations, encouraging discussions with executives from several companies and the easing of the lockdown in Shanghai. The outlook on the pandemic front has also clearly improved.

The fund's Japan weighting is likewise about 40 percent, with a focus on globally active companies that are world leaders in their target markets and that have impressive innovative skills. Examples here are the pharmaceutical companies Daiichi Sankyo and Takeda or the medtech companies Olympus and Terumo. The portfolio is rounded out with a selection of Indian, Korean, Australian and Thai stocks. Half of the portfolio is therefore ideal for investing in emerging Asian countries that are making great strides in modernizing their healthcare systems and the other half offers access to highly innovative healthcare players in the region's developed countries.

Solid Results

Asian healthcare companies continued to report very solid quarterly results even during the recent sell-off, so valuations have fallen to very attractive levels, especially for Chinese stocks. The average PEG ratio for the fund's Chinese investments, which is based on mid-term EPS estimates, is currently at 0.8, which is lower than it has ever been since the fund's conception. This corresponds to a discount of just over 20 percent versus the historical average. The portfolio's overall PEG ratio is 1.4. The average estimated sales growth of all portfolio companies for the coming years is also highly attractive at 24.1 percent p.a.
Asia’s Rapidly Expanding Healthcare Market

The historically low valuation combined with still intact fast top-line growth offers investors with a mid-to long-term investment horizon extremely attractive entry points.

- More Information about Bellevue Asset Management [here](#)

**Oliver Kubli** has been Managing Director, Head Portfolio Management Healthcare Funds & Mandates since 2015. Previously, he worked as Senior Portfolio Manager at Zürcher Kantonalbank and was a member of the Executive Board and Head Portfolio Management at Adamant Biomedical Investment AG. He completed his studies in business administration at the Zurich University of Applied Sciences in Winterthur and is a CFA charterholder.


Disclaimer: This document is neither directed to, nor intended for distribution or use by, any person or entity who is a citizen or resident of any locality, state, country or jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. The information and data presented in this document are not to be considered as an offer to buy or sell or an invitation to subscribe any securities or financial instruments. The information, opinions and estimates contained in this document reflect a judgment at the original date of release and are subject to change without notice. Liability for the accuracy or completeness of all information in this document is expressly disclaimed. This information does not take into account the specific or future investment objectives, the financial or tax situation or the particular needs of any specific recipient This document does not constitute independent investment research. Interested investors should always seek professional advice before making an investment decision. The information in this document is provided without any guarantees or warranties, for information purposes only, and is intended only for the personal use of the recipient. Every investment involves some risk, especially with regard to of fluctuations in value and return. Investments in foreign currency involve the additional risk that a foreign currency might lose value against an investor's reference currency. This document does not reflect all possible risk factors associated with an investment in the aforementioned securities or financial instruments. Historical performance data and financial market scenarios are no guarantee or indicator of current and future performance. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions. Commissions and costs adversely affect performance. Financial transactions should only be carried out after thorough study of the current prospectus and are only valid on the basis of/or/and are subject to the terms given in the most recently published prospectus and annual or semi-annual report. Bellevue Funds (Lux) SICAV is admitted for public distribution in Switzerland. Representative in Switzerland: Waystone Fund Services (Switzerland) SA, Avenue Villamont 17, CH-1005 Lausanne. Paying Agent in Switzerland: DZ PRIVATBANK (Schweiz) AG, Münsterhof 12, P.O. Box, CH-8022 Zurich. Bellevue Funds (Lux) SICAV is admitted for public distribution in Austria. Paying and information agent: ERSTE BANK der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna. The Bellevue Funds (Lux) SICAV is admitted for public distribution in Germany. Paying and information agent: ACOLIN Europe GmbH, Reichenaustrasse 11a-c, D-78467 Constance. Bellevue Funds (Lux) SICAV is registered in the CNMV registry of foreign collective
Asia’s Rapidly Expanding Healthcare Market
Category: Advertorial Tuesday, 30 August 2022 12:15

investment schemes distributed in Spain, under registration number 938. Representative: atl Capital, Calle de Montalbán 9, ES-28014 Madrid. Prospectus, Key Investor Information Document (“KIID”), the articles of association as well as the annual and semi-annual reports of the Bellevue Funds under Luxembourg law are available free of charge from the above mentioned representative, paying, facilities and information agents as well as from Bellevue Asset Management AG, Seestrasse 16, CH-8700 Kusnacht. With respect to fund units distributed in or from Switzerland, the place of performance and jurisdiction is established at the registered office of the representative.

Singapore: This marketing document is issued by Bellevue Asset Management AG, which is an authorized asset manager subject to the supervision of the Swiss Financial Market Supervisory Authority (FINMA) and acts as an Investment Manager of the Bellevue Funds (Lux) SICAV. Bellevue Asia Pacific Healthcare is a subfund of Bellevue Funds (Lux). "The offer or invitation to subscribe for or purchase shares (the “Shares”) in the Sub-Fund of Bellevue Funds (Lux) (the “Fund”), which is the subject to this Information Memorandum, is exempt offer made only: (i) to "institutional investors" pursuant to Section 304 of the Securities and Futures Act, Chapter 289 of Singapore (the “SFA”), (ii) to "relevant persons" pursuant to Section 305(1) of the Act, (iii) to persons who meet the requirements of an offer made pursuant to Section 305(2) of the Act, and in accordance with the conditions specified in Section 305 of the Act, or (iv) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the Act. The Fund and the Sub-Fund are not authorized or recognized by the Monetary Authority of Singapore (the “MAS”) and the Shares are not allowed to be offered to the retail public in Singapore. The Sub-Fund is a restricted scheme under the Sixth Schedule to the Securities and Futures (Offers of Investments) (Collective Investment Schemes) Regulations of Singapore. This Information Memorandum is not a prospectus as defined in the SFA and accordingly, statutory liability under the SFA in relation to the content of prospectuses does not apply. The MAS assumes no responsibility for the contents of this Information Memorandum. You should consider carefully whether the investment is suitable for you and whether you are permitted (under the SFA, and any laws or regulations that are applicable to you) to make an investment in the Shares. If in doubt, you should consult your legal or professional advisor. This Information Memorandum has not been registered as a prospectus with the MAS. Accordingly, this Information Memorandum, the Prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of Shares may not be circulated or distributed, nor may Shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to any persons in Singapore except in accordance with the restrictions and conditions under the SFA. By subscribing for Shares pursuant to the exempt offer under this Information Memorandum, you are required to comply with restrictions and conditions under the SFA in relation to your offer, holding and subsequent transfer of Shares."

Hong Kong: This section has been prepared solely for Hong Kong investors who invest or propose to invest in Shares of Bellevue Funds (Lux) (the “Company”) in Hong Kong. Investors in Hong Kong should read this supplement in conjunction with the Prospectus for the Company (the “Prospectus”). References to the Prospectus are to be taken as references to that document as supplemented hereby. In addition, words and expressions defined in the Prospectus, unless otherwise defined below, shall bear the same meaning when used herein.